E-Mail Alert

Add your e-mail address to receive forthcoming issues of this journal:

Journal Browser

Journal Browser

Special Issue "Marine Antimicrobial Agents"

A special issue of Marine Drugs (ISSN 1660-3397).

Deadline for manuscript submissions: 31 August 2018

Special Issue Editor

Guest Editor
Dr. Miguel O. Mitchell

American Institutes for Research, 1000 Thomas Jefferson St NW, Washington, DC 20007, USA
Website | E-Mail
Interests: antibacterial agents; cation-pi and sigma hole-based protein–ligand complex investigations; the interface of chemistry and art; improving low-income accessibility of hands-on chemical instrumentation-based experiments in analytical chemistry and biochemistry

Special Issue Information

Dear Colleagues,

This Special Issue contains communications, full research papers, and reviews pertaining to the following topics:

(1) Purification, spectroscopic structure elucidation, and biological characterization (with requisite in vitro antibacterial MIC (uM) and mammalian cytotoxicity study (uM)) of novel antibacterial compounds derived from marine organisms.

Marine antibacterial compounds include:

- bacteriostatic or bacteriocidal agents

- quorum sensing antagonists

- antiproliferative agents, e.g., inhibitors of bacterial enzymes disrupting the tissue matrix

- inhibitors of cancer-causing or cancer-aiding effects of bacterial infection

Full spectroscopic data (original proton, carbon-13, 2D NMR spectra, and HRMS) and purity confirmation (LCMS chromatogram or elemental analysis) must be included.

(2) Study of biological marine antibacterial agents

- bacteriophages 

- predatory bacteria

(must include in vitro animal cell cytotoxicity study against cells from relevant species, e.g., poultry cell cytotoxicity for an antibacterial agent eliminating a poultry infection)

(3) Investigation of antibacterial selectivity of known or new marine antibacterial agents towards marine vs. terrestrial bacteria

(4) Mechanism of action of marine antibacterial agents, new or previously reported

Dr. Miguel O. Mitchell
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Antibacterial agent
  • Quorum-sensing antagonist
  • Predatory bacteria
  • Bacteriophage
  • Antiproliferative
  • Anticancer

Published Papers (2 papers)

View options order results:
result details:
Displaying articles 1-2
Export citation of selected articles as:

Research

Open AccessArticle Antimicrobial Peptide Epinecidin-1 Modulates MyD88 Protein Levels via the Proteasome Degradation Pathway
Mar. Drugs 2017, 15(11), 362; doi:10.3390/md15110362
Received: 27 October 2017 / Revised: 10 November 2017 / Accepted: 14 November 2017 / Published: 16 November 2017
PDF Full-text (2312 KB) | HTML Full-text | XML Full-text
Abstract
The cationic antimicrobial peptide epinecidin-1 was identified from Epinephelus coioides and possesses multiple biological functions, including antibacterial, antifungal, anti-tumor, and immunomodulatory effects. In addition, epinecidin-1 suppresses lipopolysaccharide (LPS)-induced inflammation by neutralizing LPS and ameliorating LPS/Toll-like receptor (TLR)-4 internalization. However, it is unclear whether
[...] Read more.
The cationic antimicrobial peptide epinecidin-1 was identified from Epinephelus coioides and possesses multiple biological functions, including antibacterial, antifungal, anti-tumor, and immunomodulatory effects. In addition, epinecidin-1 suppresses lipopolysaccharide (LPS)-induced inflammation by neutralizing LPS and ameliorating LPS/Toll-like receptor (TLR)-4 internalization. However, it is unclear whether the actions of epinecidin-1 depend on the regulation of TLR adaptor protein MyD88 or endogenous TLR signaling antagonists, which include A20, interleukin-1 receptor associated kinase (IRAK)-M, and suppressor of cytokine signaling (SOCS)-1. Our results demonstrate that epinecidin-1 alone does not affect A20, IRAK-M, or SOCS-1 protein levels. However, pre-incubation of epinecidin-1 significantly inhibits LPS-induced upregulation of A20, IRAK-M, and SOCS-1. In addition, epinecidin-1 significantly reduces the abundance of MyD88 protein. Both MG132 (a specific proteasome inhibitor) and Heclin (a specific Smurf E3 ligase inhibitor) are able to abolish epinecidin-1-mediated MyD88 degradation. Thus, our data suggest that epinecidin-1 directly inhibits MyD88 via induction of the Smurf E3 ligase proteasome pathway. Full article
(This article belongs to the Special Issue Marine Antimicrobial Agents)
Figures

Figure 1

Open AccessArticle Diversity and Antimicrobial Potential of Predatory Bacteria from the Peruvian Coastline
Mar. Drugs 2017, 15(10), 308; doi:10.3390/md15100308
Received: 6 September 2017 / Revised: 25 September 2017 / Accepted: 9 October 2017 / Published: 12 October 2017
PDF Full-text (4488 KB) | HTML Full-text | XML Full-text | Supplementary Files
Abstract
The microbiome of three different sites at the Peruvian Pacific coast was analyzed, revealing a lower bacterial biodiversity at Isla Foca than at Paracas and Manglares, with 89 bacterial genera identified, as compared to 195 and 173 genera, respectively. Only 47 of the
[...] Read more.
The microbiome of three different sites at the Peruvian Pacific coast was analyzed, revealing a lower bacterial biodiversity at Isla Foca than at Paracas and Manglares, with 89 bacterial genera identified, as compared to 195 and 173 genera, respectively. Only 47 of the bacterial genera identified were common to all three sites. In order to obtain promising strains for the putative production of novel antimicrobials, predatory bacteria were isolated from these sampling sites, using two different bait organisms. Even though the proportion of predatory bacteria was only around 0.5% in the here investigated environmental microbiomes, by this approach in total 138 bacterial strains were isolated as axenic culture. 25% of strains showed antibacterial activity, thereby nine revealed activity against clinically relevant methicillin resistant Staphylococcus aureus (MRSA) and three against enterohemorrhagic Escherichia coli (EHEC) strains. Phylogeny and physiological characteristics of the active strains were investigated. First insights into the chemical basis of the antibacterial activity indicated the biosynthetic production of the known compounds ariakemicin, kocurin, naphthyridinomycin, pumilacidins, resistomycin, and surfactin. However, most compounds remained elusive until now. Hence, the obtained results implicate that the microbiome present at the various habitats at the Peruvian coastline is a promising source for heterotrophic bacterial strains showing high potential for the biotechnological production of antibiotics. Full article
(This article belongs to the Special Issue Marine Antimicrobial Agents)
Figures

Figure 1

Back to Top